4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
11.32
-0.09 (-0.79%)
At close: Oct 30, 2025, 4:00 PM EDT
11.43
+0.11 (0.97%)
After-hours: Oct 30, 2025, 4:53 PM EDT
4D Molecular Therapeutics Revenue
4D Molecular Therapeutics had revenue of $15.00K in the quarter ending June 30, 2025, with 200.00% growth. This brings the company's revenue in the last twelve months to $33.00K, down -99.84% year-over-year. In the year 2024, 4D Molecular Therapeutics had annual revenue of $37.00K, down -99.82%.
Revenue (ttm)
$33.00K
Revenue Growth
-99.84%
P/S Ratio
16,020.36
Revenue / Employee
$145
Employees
227
Market Cap
528.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 37.00K | -20.69M | -99.82% |
| Dec 31, 2023 | 20.72M | 17.59M | 562.29% |
| Dec 31, 2022 | 3.13M | -14.91M | -82.65% |
| Dec 31, 2021 | 18.04M | 4.43M | 32.52% |
| Dec 31, 2020 | 13.61M | 6.63M | 94.85% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| Eli Lilly and Company | 59.42B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
FDMT News
- 13 days ago - 4DMT Announces New Employment Inducement Grants - GlobeNewsWire
- 16 days ago - 4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference - GlobeNewsWire
- 17 days ago - 4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation - GlobeNewsWire
- 4 weeks ago - 4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors - Seeking Alpha
- 7 weeks ago - 4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - 4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness - GlobeNewsWire
- 2 months ago - 4DMT to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - 4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewsWire